Compare Cassava Sciences Inc (FLNA) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Xcel Energy Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Xcel Energy Inc trades at $73.78 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 1162.9× Cassava Sciences Inc's market cap, and Xcel Energy Inc pays a 3.23% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Xcel Energy Inc for 61 Days on average.
| FLNA | XEL | |
|---|---|---|
Market Cap | $39.40M | $45.82B |
Volume | 759,018 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $4.64 | $83.91 |
52-Week Low | $0.68 | $69.39 |
Typical Hold Time | 37 Days | 61 Days |
Enterprise Value | -$43.28M | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Xcel Energy (XEL) trades at $73.36, up 1.3% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent earnings beats. Recent news highlights growth from data center power demand and a $60B capital investment plan. Technical indicators show bullish momentum with support at $72-73 and resistance at $74-75 levels.
XEL presents a compelling investment case with analyst consensus target of $90.83 (24% upside) and 63% buy ratings. Key opportunities include infrastructure expansion and rising power demand, while risks involve wildfire liabilities and high capital expenditure. The stock's valuation at 20.1 P/E appears reasonable given growth prospects and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
